Global Anticonvulsants Market Size Hit USD 23.71 Billion at a CAGR of 2.5% in 2032

PRESS RELEASE
Published March 28, 2023

The global anticonvulsants market size was USD 18.57 Billion in 2022 and is expected to register a revenue CAGR of 2.5% over the forecast period, according to the latest report by Reports and Data. Revenue growth of the market is expected to be driven by government programs that support drug development and marketing including funds and investments.

Individuals are more inclined to experience depression and other mental health disorders. They are also becoming much more health-conscious and have started realizing the importance of non-pharmaceutical, noninvasive therapies in the fight against such diseases. In comparison to more than 16% of females in the same age range, five males between the ages of 15 and 19 were reported by UNICEF to have a mental condition in Europe. Anxiety and stress account for more than half of the 9 million youngsters (10–19) who have mental health issues. Rising number of drug approvals by regulatory bodies is also leading to market expansion. For instance, on 24 March 2022, the pharmaceutical company Lupin announced that the Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application (ANDA), Vigabatrin for Oral Solution USP (500 mg), which was intended to treat epilepsy.

Companies profiled in the global market report include Olympus Corporation., Intuitive Surgical, Brainlab AG, Asensus Surgical US, Inc., CMR Surgical Ltd., Avateramedical GmbH, Medtronic, B. Braun SE, Boston Scientific Corporation, and AKTORmed GmbH.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/5918

Market Overview:

The research report assesses the market dynamics, market landscape, company profiles, production and manufacturing capacity, year-on-year growth rate, SWOT analysis, and Porter’s Five Forces analysis. The report estimates the market size, market growth, and provides an accurate forecast for the key segments of the market for the forecast period of 2022-2032. The report also covers an in-depth analysis of the key competitors of the market, along with their growth strategies and business expansion plans.

The Anticonvulsants Market has been segmented into key regions of the world and offers an analysis of growth rate, market share, market size, current and emerging trends, production and consumption ratio, industrial chain analysis, demand and supply, import and export, revenue contribution, and presence of key players in each region. A country-wise analysis of the market is offered in the report to gain a better understanding of the regional spread and progress of the Anticonvulsants Market.

Further key findings from the report suggest,

  • The second-generation segment is expected to account for largest revenue share over the forecast period. Factors such as enhanced tolerance reduced adverse effects, and increased efficacy is driving the revenue growth of this segment. The number of medicines available to treat seizure disorders has doubled as a result of the inclusion of these second-generation drugs. These include zonisamide, gabapentin (Neurontin), levetiracetam (Keppra), felbamate (Felbatol), lamotrigine (Lamictal), oxcarbazepine (Trileptal), gabapentin (Neurontin) (Zonegran), and tiagabine (Gabitril).
  • The capsule segment is expected to register a significantly fast revenue growth rate over the forecast period. Individuals are more likely to accept capsules since they have no taste or odor. Patient compliance is much improved by capsules, which also improves treatment outcomes If a patient has trouble swallowing, it can be helpful for them to open the capsule and spread the contents on food like applesauce.
  • The hospital segment is expected to account for a major revenue share over the forecast period. Factors such as an increase in the number of pharmacies in hospitals that cater to psychiatric, neurological, and other areas of medicine, lower treatment costs, and a rise in the prevalence of mental health problems globally. Services for both serious and complicated diseases are continuously offered. To better meet patient needs and increase therapeutic effectiveness, hospitals engage in Research and Development (R&D). They concentrate their limited resources on effective referral systems.
  • The market in North America accounted for the largest revenue share in 2022. Factors such as increased public awareness of mental health issues, an increase in these disorders, corporate R&D efforts, and drug approvals are major factors contributing to market revenue growth in this region. Rising treatment and disease diagnosis rates of neurological conditions, along with an increasing number of awareness campaigns regarding the availability of unique drugs and treatment options, as well as the presence of favorable reimbursement policies in this region are expected to drive market revenue growth in this region.

To understand how our Anticonvulsants Market can bring difference to your business strategy:https://www.reportsanddata.com/report-detail/anticonvulsants-market

For the purpose of this report, Reports and Data has segmented the global anticonvulsants market based on drug type, application, drug generation, dosage, end-use, and region:

Drug Type Outlook (Revenue, USD Billion; 2019-2032)

  • Barbiturate
  • α-Amino-3-Hydroxy-5-Methyl-4-isoxazole Propionic acid (AMPA)
  • Carbamate Anticonvulsants Energy Management
  • Carbonic Anhydrase Inhibitor
  • Valproylamides (Amide Valproate)
  • Others

Application (Revenue, USD Billion; 2019-2032)

  • Epilepsy
  • Fibromyalgia
  • Neuropathic Pain
  • Anxiety
  • Migraine
  • Bipolar Disorder
  • Borderline Personality Disorder
  • Others

Drug Generation (Revenue, USD Billion; 2019-2032)

  • First Generation
  • Second Generation
    • Third Generation

Dosage (Revenue, USD Billion; 2019-2032)

  • Capsule
  • Tablet
  • Cream
  • Liquid
  • Rectal Gel
  • Others

End-Use (Revenue, USD Billion; 2019-2032)

  • Hospitals
  • Clinics
  • Ambulatory Surgical Clinics
  • Others

Regional Outlook (Revenue, USD Billion; 2019-2032)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Sweden
    • BENELUX
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Israel
    • Rest of MEA

Request a customization of the report : https://www.reportsanddata.com/request-customization-form/5918

 Key Advantages of Anticonvulsants Market Report:

  • Identification and analysis of the market size and competition
  • Qualitative and quantitative analysis of the market data
  • Data validated by industry experts after extensive primary and secondary research
  • Extensive regional analysis of the Anticonvulsants industry
  • Profiling of key players along with their business overview, business strategies, deals and partnerships, and product portfolio
  • SWOT and Porter’s Five Forces Analysis for in-depth understanding of the competitive landscape
  • Feasibility analysis and investment analysis to enable strategic investment decisions
  • Analysis of opportunities, drivers, restraints, challenges, risks, and limitations

Conclusively, all aspects of the Anticonvulsants Market are quantitatively as well qualitatively assessed to study the global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail:
[email protected]
Reports and Data | Web:
www.reportsanddata.com
Check our upcoming research reports @
https://www.reportsanddata.com/upcoming-reports
Visit our blog for more industry updates @ https://www.reportsanddata.com/blogs

Image Credit

Browse More Reports:

https://www.biospace.com/article/tuberculosis-diagnostics-market-to-reach-usd-3-58-billion-by-2027-says-reports-and-data/

https://www.biospace.com/article/cell-sorting-market-to-reach-usd-805-1-million-by-2027-says-reports-and-data/

https://www.biospace.com/article/parenteral-nutrition-market-to-reach-usd-9-158-7-million-by-2028-says-reports-and-data/

https://www.biospace.com/article/syringes-and-needles-market-size-to-reach-usd-36-13-billion-in-2028-says-reports-and-data/

https://www.biospace.com/article/increasing-number-of-blood-donation-camps-around-the-globe-would-provide-new-opportunities-for-blood-bag-businesses-to-expand-reports-and-data/

 

The post Global Anticonvulsants Market Size Hit USD 23.71 Billion at a CAGR of 2.5% in 2032 appeared first on Market O Graphics.

Reports and Data